Published • loading... • Updated
New hope for breast cancer patients as life-extending drug now on NHS in England
The drug can extend life by almost seven months on average, and campaigners say about 1,000 women a year could benefit.
- On Thursday, the National Institute for Health and Care Excellence confirmed Enhertu is now available for roughly 1,000 women in England with HER2-low metastatic breast cancer following a newly agreed "commercial solution."
- NICE reversed its 2024 rejection after a UK-USA trade deal increased the cost-effectiveness threshold per Quality-Adjusted Life Year from £30,000 to £35,000, alongside new quality-of-life assessment methods introduced in August.
- Patient Paula Van Santen, 51, from Banbury, described the approval as a "new sense of hope," as Enhertu can extend life by nearly seven months on average, with some patients living up to three years longer.
- Health Secretary Yvette Cooper called the decision "life-changing," while Breast Cancer Now chief executive Claire Rowney noted the delay caused "devastating cost" for patients who missed treatment opportunities.
- AstraZeneca UK country president Tom Keith-Roach stated the milestone aligns England with Scotland and 26 other European countries, while officials now look to Wales and Northern Ireland to expand availability.
Insights by Ground AI
7 Articles
7 Articles
The IndependentReposted by 
The Independent (US)
The Independent (US)Life-extending breast cancer drug made available on NHS after U-turn
The National Institute for Health and Care Excellence (Nice) announced that it has reversed an initial decision to reject the drug for widespread use for the NHS in England
·London, United Kingdom
Read Full Article
A Life-Extending Breast Cancer Drug Finally Comes to England
·New York, United States
Read Full Article
Women in England with incurable breast cancer to get life-extending drug on NHS
Thousands with HER2-low advanced breast cancer will have access to Enhertu after ministers strike deal on price Thousands of women in England with incurable breast cancer will get access to a life-extending drug on the NHS after negotiations over its cost proved successful. About 1,000 women a year with HER2-low advanced breast cancer will be…
Coverage Details
Total News Sources7
Leaning Left3Leaning Right1Center2Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 33%
R 17%
Factuality
To view factuality data please Upgrade to Premium
